NDAORALSYRUP1 Generic Approved
Approved
Jan 1965
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 6d ago · AI intelligence enriched 4w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MESTINON (pyridostigmine bromide) is an oral syrup anticholinesterase agent approved in 1965 that works by inhibiting the destruction of acetylcholine at the myoneural junction, thereby facilitating neuromuscular transmission. It is primarily used to treat myasthenia gravis and can reverse neuromuscular blockade from nondepolarizing muscle relaxants during anesthesia. Compared to neostigmine, pyridostigmine demonstrates a longer duration of action and lower incidence of bradycardia, salivation, and gastrointestinal side effects. As a well-established treatment with decades of clinical use, it remains a foundational therapy in neuromuscular disease management.
$0.0BPart D
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Testing Mestinon and Exercise in Fibromyalgia
Started Sep 2002
178 enrolled
Fibromyalgia
Career Relevance
With zero linked job openings currently reported, career opportunities on MESTINON are minimal and declining as the product approaches loss of exclusivity. Roles, if available, would be limited to brand management focused on generic transition planning, market access specialists managing formulary negotiations, and possibly medical science liaisons maintaining relationships with neuromuscular specialists. Relevant skills would include lifecycle management, generic competitive strategy, and payer relations rather than primary drug development expertise.
Worked on MESTINON at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.